Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 5Ipilimumab 3Everolimus 3lutetium Lu 177 dotatate 2cabozantinib 2atezolizumab 2Temozolomide 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Etoposide 2Cisplatin 2Capecitabine 2tivozanib 1sintilimab 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1copper dotatate CU-64 1belinostat 1avelumab 1Sunitinib 1Somatostatin 1Drug Therapy 1Copper 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 164Cu-DOTATATE 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Copper × NET × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡